Biodesix (BDSX) Competitors

Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Which has more volatility and risk, BDSX or XGN?

Biodesix has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Does the media prefer BDSX or XGN?

In the previous week, Exagen had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Biodesix. Exagen's average media sentiment score of 0.99 beat Biodesix's score of 0.00 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, BDSX or XGN?

Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$71.32M	0.93	-$42.93M	-$0.29	-1.56
Exagen	$55.64M	3.99	-$15.11M	-$0.89	-11.35

Do analysts recommend BDSX or XGN?

Biodesix presently has a consensus target price of $1.75, suggesting a potential upside of 285.97%. Exagen has a consensus target price of $11.25, suggesting a potential upside of 11.39%. Given Biodesix's higher possible upside, equities research analysts plainly believe Biodesix is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Exagen	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals believe in BDSX or XGN?

21.0% of Biodesix shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 30.1% of Biodesix shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is BDSX or XGN more profitable?

Exagen has a net margin of -28.85% compared to Biodesix's net margin of -53.66%. Exagen's return on equity of -130.38% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-53.66%	-269.67%	-43.94%
Exagen	-28.85%	-130.38%	-34.69%

Summary

Exagen beats Biodesix on 11 of the 16 factors compared between the two stocks.